IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1 / Phase 2	2025-06-03		NCT06119685

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Indapta Therapeutics, INC.	1

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Atrium Health Wake Forest Baptist	Winston-Salem	United States	52
Emory University Hospital	Atlanta	United States	131
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center	Lake Mary	United States	1
NEXT Oncology Virginia	Fairfax	United States	40
NYP/Weill Cornell Medical Center	New York	United States	128
Providence Cancer Institute Franz Clinic	Portland	United States	25
Rhode Island Hospital	Providence	United States	229
Scri Oncology Partners	Nashville	United States	156
University Hospitals Cleveland	Cleveland	United States	9
University of Minnesota	Minneapolis	United States	325
University of Texas MD Anderson Cancer Center	Houston	United States	192
Valkyrie Clinical Trials	Los Angeles	United States	1